Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small molecule drugs for the treatment of inflammatory, cancer, and liver diseases. The company's proprietary technology targets A3 adenosine receptors (A3AR), which play a crucial role in these diseases. Can-Fite’s lead drug candidates include Piclidenoson, in advanced stages for psoriasis and rheumatoid arthritis, and Namodenoson, undergoing trials for hepatocellular carcinoma (liver cancer) and non-alcoholic steatohepatitis (NASH). With a robust pipeline and strategic focus on addressing significant unmet medical needs, Can-Fite aims to bring innovative therapies to market, leveraging their extensive clinical research and development capabilities

Fortress Biotech, Inc. (FBIO) is a biopharmaceutical company that employs an innovative model by providing comprehensive infrastructure and support to its subsidiary companies. This model allows each subsidiary to focus on specific therapeutic areas, such as oncology, gene therapy, dermatology, and anti-infectives, fostering specialized management and efficient drug development. By diversifying its portfolio and engaging in strategic partnerships, Fortress Biotech mitigates risks associated with drug development and maximizes potential rewards. This approach not only enhances the success rate of its subsidiaries but also drives the development of groundbreaking therapies for unmet medical needs.

Citius Pharmaceuticals is an emerging biopharmaceutical company dedicated to the development and commercialization of critical care products with unique and innovative therapies. This article delves into the company's latest advancements, research initiatives, and future prospects.

Why Daruma? We review why we selected the name: "daruma" for our company. To understand we need to understand the historical and cultural significance of the Daruma doll in Japanese tradition, explaining its symbolism and how it is used to set and achieve personal goals. We explain how we have adapted the traditional Daruma into our logo for DarumaBio Capital LLC

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company dedicated to discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human diseases and alleviate suffering. The company's diverse pipeline includes candidates targeting central nervous system (CNS) disorders such as fibromyalgia and PTSD, immunology, infectious diseases including COVID-19, and biodefense. With its lead product candidate TNX-102 SL in Phase 3 clinical trials for fibromyalgia, Tonix is committed to advancing its innovative therapies through rigorous clinical development and strategic partnerships to address significant unmet medical needs​